Analysed KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) News Sources
Endometriosis Market Expected to Achieve Significant CAGR During the Forecast Period (2026-2036) Driven by Innovative Treatment Options | DelveInsight
12-03-2026
yahoo.com
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
07-10-2025
yahoo.com
Is Now the Right Moment for Kissei Pharmaceutical After Its 2025 Earnings Jump?
15-09-2025
yahoo.com
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront
18-08-2025
yahoo.com
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
06-08-2025
yahoo.com
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
05-08-2025
yahoo.com
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan
31-07-2025
pharmaceutical-technology.com
What is the current price of KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS)?
The current price of KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) is $0.
KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) since the previous trading day is $None.
KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS)?
The most recent average sentiment score for KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) is 82 out of 100.
What is the most recent average sentiment for KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS)?
The most recent sentiment for KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS) is .
SEC-8K** Filing Available For KISSEI PHARMACEUTICAL CO LTD (KSPHF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.